Albany, New York (PRWEB) September 24, 2014
The global erectile dysfunction drugs market was worth $ 4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $ 3.4 billion in 2019.
All facts and figures have be provided through a research report titled Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 2019, published by Transparency Market Research.
To browse through the research report, or to view the ToC, please visit: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $ 1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.
Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.
The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.
For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550
By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.
The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.
Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453
Find More Erectile Dysfunction Press Releases